INmune Bio announces the successful completion of the extended stability validation for XPro continuous storage in solution at 2-8C. The 24 and 30-month stability test samples passed all chemistry and potency assays; allowing the Company to make a conservative claim of 24-month stability. The 24-month stability claim is consistent with other pegylated cytokines, such as alpha-interferon, and allows the Company to design a global supply chain using proven and established systems. With this data, the company can benefit from such existing systems that use temperature controlled and monitored shipment of liquid-formulation drugs at 2-8C, which is routine across the pharmaceutical industry. The 24-month stability data confirms that XPro can mirror these established supply chain strategies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay
- INmune Bio presents data on INB03’s role as immune check point
- INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28
- INmune Bio reports ‘significant’ EEG improvement in patients treated with Xpro
- INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™